Istesso
Private Company
Total funding raised: $30M
Overview
Istesso is a private, clinical-stage biotech founded in 2018, headquartered in Oxford, UK. The company is developing a groundbreaking platform of oral regenerative medicines based on mitochondrial Complex I modulators (MCMs), with a lead asset, leramistat, in Phase 2 trials. Its strategy targets a paradigm shift in chronic disease management by focusing on tissue repair and restoration of health, moving beyond symptomatic control. Istesso's pipeline has blockbuster potential across multiple age-related chronic diseases, positioning it as a leader in a nascent but highly promising therapeutic field.
Technology Platform
Mitochondrial Complex I Modulators (MCMs) - a novel class of oral small molecule drugs designed to restore mitochondrial function to activate endogenous tissue repair and regeneration pathways.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Istesso operates in a nascent competitive space for oral pharmacological tissue regeneration. It faces indirect competition from palliative standard-of-care drugs across multiple disease areas and longer-term competition from other regenerative modalities like cell and gene therapies, which are often invasive and complex. Its primary competition is the high biological barrier to achieving regeneration with a small molecule.